Mounjaro Online UK

Mounjaro contains tirzepatide, a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

It is administered by subcutaneous injection and is licensed for the treatment of type 2 diabetes mellitus and, in certain jurisdictions, for chronic weight management in adults with obesity or overweight with weight-related comorbidities.

Tirzepatide acts on both the GIP and GLP-1 receptors, producing effects that exceed those of selective GLP-1 receptor agonists.

It enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon, slows gastric emptying, and reduces appetite and caloric intake.

The dual agonism is thought to provide additive or synergistic benefits on glycaemic control and body weight.

The SURPASS and SURMOUNT clinical trial programmes demonstrated that tirzepatide achieved superior reductions in HbA1c and body weight compared with semaglutide 1 mg and placebo.

In the SURMOUNT-1 trial, patients achieved an average weight loss of approximately 22.

5% of body weight at the highest dose over 72 weeks, making Mounjaro one of the most effective pharmacological weight-management treatments currently available.

Mounjaro is administered as a subcutaneous injection once weekly, on the same day each week, at any time of day, with or without meals.

Inject into the abdomen, thigh, or upper arm, rotating injection sites each week. The dose is escalated gradually over several months to the target dose.

If you miss a dose and the next scheduled dose is more than four days away, inject as soon as possible; otherwise, skip the missed dose and resume the usual weekly schedule.

The starting dose is 2.5 mg once weekly for four weeks, then increased to 5 mg once weekly. If additional glycaemic control or weight loss is needed, the dose may be increased in 2.

5 mg increments at intervals of at least four weeks, to a maximum of 15 mg once weekly. Available strengths are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.

No dose adjustment is required for renal or hepatic impairment, though use in severe hepatic impairment has not been studied.

Very common (more than 1 in 10): nausea, diarrhoea, decreased appetite, vomiting, constipation.

Gastrointestinal adverse events are most frequent during dose escalation and generally diminish over time.

Common (1 in 10 to 1 in 100): abdominal pain, dyspepsia, gastro-oesophageal reflux, injection site reactions, fatigue, hypoglycaemia (especially with sulfonylureas or insulin), dizziness, alopecia, eructation, flatulence.

Uncommon (1 in 100 to 1 in 1,000): pancreatitis, cholelithiasis, cholecystitis, increased heart rate, acute kidney injury (secondary to dehydration).

Rare: thyroid C-cell tumours (observed in animal studies; clinical relevance in humans is uncertain).

Pancreatitis has been reported with incretin-based therapies. Discontinue Mounjaro if pancreatitis is suspected.

Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use tirzepatide.

Monitor for gallbladder events during rapid weight loss. Maintain adequate fluid intake to minimise dehydration risk from gastrointestinal side effects.

Patients on insulin or sulfonylureas may need dose reduction to prevent hypoglycaemia. Discuss reliable contraception, as weight loss may increase fertility in women with polycystic ovary syndrome.

Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, known hypersensitivity to tirzepatide or any excipient, and during pregnancy and breastfeeding.

It should not be used in patients with type 1 diabetes.